CN201847800U - Biodegradable drug-coated support for coronary artery - Google Patents
Biodegradable drug-coated support for coronary artery Download PDFInfo
- Publication number
- CN201847800U CN201847800U CN2010205092350U CN201020509235U CN201847800U CN 201847800 U CN201847800 U CN 201847800U CN 2010205092350 U CN2010205092350 U CN 2010205092350U CN 201020509235 U CN201020509235 U CN 201020509235U CN 201847800 U CN201847800 U CN 201847800U
- Authority
- CN
- China
- Prior art keywords
- polymer support
- support
- sacculus
- coronary artery
- biodegradable polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The utility model relates to a biodegradable drug-coated support for coronary artery, which comprises conveying equipment and a biodegradable polymer support; the conveying equipment comprises a control end, a catheter and a sacculus; the control end and the catheter are connected together; the top end of the catheter is provided with the sacculus; the biodegradable polymer support is arranged on the periphery of the sacculus; the biodegradable polymer support is provided with a drug carrier; and a thin drug layer is coated on the surface of the biodegradable polymer support. The biodegradable drug-coated support for coronary artery has the beneficial effects that: after the biodegradable polymer support is absorbed, blood vessels can recover the normal contractibility, so that the blood vessels are prevented from getting narrow again, and the re-narrowing incidence rate of the blood vessels can be reduced to 1 percent to 2 percent; the phenomenon that the power of the blood vessels disappears caused by an ordinary biodegradable polymer support can be prevented; a plurality of intervention can be carried out at the same lesion; and the biodegradable drug-coated support for coronary artery can be used for children with congenital diseases, so that frequent re-intervention treatment is not needed.
Description
Technical field
This utility model relates to a kind of biodegradability coronary artery medicine and is coated with support.
Background technology
Heart is one of great organ of workload in the human body, needs continuous rule to beat blood is delivered to whole body, and therefore, the probability that breaks down is very high.Be responsible for being the coronary artery that three rings are overlying on heart surface to the circulation nutrient of heart own, the most common pathological changes is because the narrow oxygen supply deficiency that causes, and then cause angina pectoris or Secondary cases myocardial infarction, necrosis, even cause heart failure death, be present mortality rate disease with high.The method of current treatment coronary stricture mainly contains three major types, routine medication, bypass surgery and insertion type cardiovascular anaplasty, wherein insertion type cardiovascular formation art is present method the safest, evident in efficacy, and arteria coronaria biodegradability polymer support is the crucial equipment of this treatment means.
The arteria coronaria interventional therapy develops into today, experienced coronary artery balloon expandable (PTCA), arteria coronaria is implanted into the naked biodegradability polymer support of metal (BMS) and arteria coronaria is implanted into three epoch of medicament elution biodegradability polymer support (DES), restenosis rate drops to 20%～30% of the BMS epoch by 30%～50% in the blood vessel, and below 10% of DES epoch, illustrate that DES has certain curative effect aspect the solution neointimal hyperplasia problem.
The problem that DES may cause the later stage thrombosis taking place in recent years, further developed coating degradable medicaments slow release arteria coronaria biodegradability polymer support, wishes to eliminate the thrombosis problem that coating causes.These biodegradability polymer supports all are nonvolatil being implanted in the blood vessel, long-term pathology shows may cause adverse consequences, the fracture of biological example degradability polymer support, hinders X-ray according to shadow and replant difficulty into the biodegradability polymer support.
The utility model content
The purpose of this utility model provides a kind of biodegradability coronary artery medicine and is coated with support, and the biodegradability polymer support is absorbed the back blood vessel can recover normal contraction, helps preventing vascular restenosis.
The purpose of this utility model is to be achieved through the following technical solutions:
A kind of biodegradability coronary artery medicine is coated with support, comprise conveying equipment and biodegradability polymer support, described conveying equipment is made of control end, conduit and sacculus, control end and conduit are connected as a single entity, the top of conduit is provided with sacculus, be attached on the conduit during sacculus unaerated, the sacculus periphery is provided with the biodegradability polymer support, and the biodegradability polymer support is not attached on the sacculus when launching.Described biodegradability polymer support is provided with pharmaceutical carrier, and described biodegradability polymer support surface scribbles the medicine thin layer.
The beneficial effects of the utility model are: the biodegradability polymer support has good biological intermiscibility and degradability, nontoxic, nonirritant, intensity height, easily machine-shaping.The biodegradability polymer support is absorbed the back blood vessel can recover normal contraction, helps preventing vascular restenosis, and the vascular restenosis incidence rate can be reduced to 1-2%; The blood vessel power that also can avoid common biodegradability polymer support to cause disappears; Can repeatedly get involved intervention in same lesion; Can be used for the congenital diseases infant, thereby do not need frequently therapeutic intervention again.
Description of drawings
With reference to the accompanying drawings this utility model is described in further detail below.
Fig. 1 is the structure chart that the described biodegradability coronary artery of this utility model embodiment medicine is coated with support.
Among the figure:
1, control end; 2, conduit; 3, sacculus; 4, biodegradability polymer support.
The specific embodiment
As shown in Figure 1, the described a kind of biodegradability coronary artery medicine of this utility model embodiment is coated with support, comprise conveying equipment and biodegradability polymer support 4, described conveying equipment is made of control end 1, conduit 2 and sacculus 3, control end 1 is connected as a single entity with conduit 2, and the top of conduit 2 is provided with sacculus 3, is attached on the conduit 2 during sacculus 3 unaerateds, sacculus 3 peripheries are provided with biodegradability polymer support 4, and biodegradability polymer support 4 is not attached on the sacculus 3 when launching.Described biodegradability polymer support 4 is provided with pharmaceutical carrier, and biodegradability polymer support 4 surfaces scribble the medicine thin layer, and the medicine on the biodegradability polymer support 4 plays anti-hemostatic tube pathological changes once more.
In the work process, earlier biodegradability polymer support 4 is transported to the lesion vessels place, sacculus 3 acts on the biodegradability polymer support 4 peripheral with it in expansion process then, biodegradability polymer support 4 can slowly launch, up to being affixed on the lesion vessels inwall, last sacculus 3 shrinks, and conveying equipment is withdrawn from, and biodegradability polymer support 4 is retained in the blood vessel.
Claims (1)
1. a biodegradability coronary artery medicine is coated with support, comprise conveying equipment, described conveying equipment is made of control end (1), conduit (2) and sacculus (3), control end (1) is connected as a single entity with conduit (2), the top of conduit (2) is provided with sacculus (3), it is characterized in that: sacculus (3) periphery is provided with biodegradability polymer support (4), and biodegradability polymer support (4) is provided with pharmaceutical carrier, and the surface of biodegradability polymer support (4) scribbles the medicine thin layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010205092350U CN201847800U (en) | 2010-08-30 | 2010-08-30 | Biodegradable drug-coated support for coronary artery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010205092350U CN201847800U (en) | 2010-08-30 | 2010-08-30 | Biodegradable drug-coated support for coronary artery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201847800U true CN201847800U (en) | 2011-06-01 |
Family
ID=44090219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010205092350U Expired - Fee Related CN201847800U (en) | 2010-08-30 | 2010-08-30 | Biodegradable drug-coated support for coronary artery |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201847800U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111956373A (en) * | 2020-08-27 | 2020-11-20 | 中山大学附属第八医院（深圳福田） | Coronary artery edge protection type stent |
-
2010
- 2010-08-30 CN CN2010205092350U patent/CN201847800U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111956373A (en) * | 2020-08-27 | 2020-11-20 | 中山大学附属第八医院（深圳福田） | Coronary artery edge protection type stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015070814A1 (en) | Drug-eluting balloon and preparation method therefor | |
| JP5777607B2 (en) | H-side branch vessel stent | |
| WO2011131115A1 (en) | Stent for bifurcated vessel | |
| WO2016173553A1 (en) | Support and drug delivery device | |
| CN204050424U (en) | A kind of medicinal balloon | |
| CN102309368A (en) | Body lumen drug-carrying bracket and preparation method thereof | |
| CN101485902B (en) | Biological degradable metal stent coated with rapamycin-probucol composite medicament | |
| CN108498208B (en) | Blood vessel support suitable for artery blood vessel | |
| CN101632606A (en) | Interventional medical device carrying medicaments | |
| CN202191582U (en) | Medicine balloon dilating catheter | |
| Rola et al. | The bioresorbable magnesium scaffold (Magmaris)—State of the art: From basic concept to clinical application | |
| CN201847800U (en) | Biodegradable drug-coated support for coronary artery | |
| CN106137486A (en) | A kind of bifurcated sacculus | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| CN204840623U (en) | Medicine elution sacculus | |
| Ural et al. | Coronary embolism complicating aortic valve endocarditis: treatment with successful coronary angioplasty | |
| WO2018059207A1 (en) | New use of amlexanox | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| CN101641059B (en) | Intracoronary stent with asymmetric drug releasing controlled coating | |
| Sigwart | Living history of medicine: vascular scaffolding, from dream to reality | |
| CN209827116U (en) | Recyclable medicine support | |
| CN104983492A (en) | Spraying liner structure and method for assisting in spraying medicine on absorbable stent | |
| CN109602523B (en) | Recoverable medicine support | |
| Feng et al. | Development history of endovascular surgery and devices | |
| CN204909753U (en) | Assist and to absorb spraying lining structure that support carries out medicine spraying |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110601 Termination date: 20150830 |
|
| EXPY | Termination of patent right or utility model |